The Effect of LDL-cholesterol and Treatment with Losartan on End-stage Renal Disease in the RENAAL Study
- Andrew M. Tershakovec, MD (andrew_tershakovec{at}merck.com)1,
- William F. Keane, MD1,
- Zhongxin Zhang, PhD1,
- Paulette A. Lyle, BS1,
- Gerald B. Appel, MD2,
- Janet B. McGill, MD3,
- Hans-Henrik Parving, MD4,
- Mark E. Cooper, MD, PhD5,
- Shahnaz Shahinfar, MD1 and
- Barry M. Brenner, MD6
- 1Merck & Co., Inc., Upper Gwynedd, PA
- 2Columbia University, New York, NY
- 3Washington University, St. Louis, MO
- 4University Hospital of Copenhagen, Copenhagen, Denmark
- 5Baker Heart Research Institute, Melbourne, Australia
- 6Renal Division, Brigham and Women's Hospital, Boston, MA
Abstract
Abstract Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/proteinuria may lower lipids but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between low-density lipoprotein cholesterol (LDL-C) levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at Year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebo-based antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL-C lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.
Footnotes
-
- Received January 31, 2007.
- Accepted December 4, 2007.
- Copyright © American Diabetes Association
